Please login to the form below
MabThera
This page shows the latest MabThera news and features for those working in and with pharma, biotech and healthcare.
Hemlibra off to a flyer as Roche raises 2019 forecasts
There was some slippage for immunology drug MabThera/Rituxan (rituximab) and Herceptin (trastuzumab) for breast cancer, with the declines seen most starkly in Europe where they fell 38% and 44% respectively.
Latest news
-
Pfizer closes on EU approval of lung cancer drug Vizimpro
Meanwhile, Sanofi picked up new labelling for cholesterol-lowering antibody Praluent (alirocumab) that included a cardiovascular risk reduction claim, while Roche’s venerable antibody drug MabThera (rituximab) added the new indication
-
Ocrevus helps Roche shrug off biosimilars in 2018
The drugmaker reported sales up 7% to 56.8bn Swiss francs ($57.1bn) for 2018, with a 7% decline in Europe caused mainly by falls for MabThera/Rituxan (rituximab) and breast ... Roche said it thinks the same pattern will be evident this year, however,
-
Imbruvica and Gazyvo approved in first non-chemo CLL use
The approval is also good news for Roche and its drug Gazyvo (obinutuzumab) which the company is trying to prove as superior next-generation version of MabThera/Rituxan (rituximab) which is
-
CHMP backs Sanofi’s all-oral sleeping sickness drug
remission with minimal residual disease greater than or equal to 0.1%, and also backed Roche’s MabThera (rituximab) for adults with severe, active granulomatosis with polyangiitis and microscopic polyangiitis in
-
Roche and AbbVie prepare to move Venclexta into first-line CLL
Gazyva is a follow-up to Roche’s big-selling Rituxan/MabThera (rituximab) anti-CD20 drug – a mainstay of CLL therapy given alongside chemotherapy – and was approved alongside chlorambucil for
More from news
Approximately 17 fully matching, plus 102 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and Herceptin.
-
Deal Watch November 2016
We are starting to see more deals covering biosimilars and this month Poland-based Mabion signed a supply and commercialisation agreement with Mylan for a biosimilar of Roche's ... competitors. The patents covering MabThera/Rituxan expired in Europe in
-
Pharma deals in June 2015
Roche has two products approved in Europe, Herceptin SC and MabThera SC, and Baxter has HyQvia approved in the US and EU, which utilise the Halozyme approach. ... Herceptin SC and MabThera SC can be administered in approximately 5 minutes by sc injection
-
Russian innovation at the crossroads
For example, in autumn 2014, BIOCAD fully pushed out Roche's Mabthera (rituximab) from public procurement.
-
Pharma deals during December 2014
Subcutaneous formulations of both MabThera and Herceptin based on the Halozyme technology have been launched by Roche.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Sanofi hires David Loew from Roche
He gradually rose up the ranks at Roche, holding senior marketing positions such as life cycle leader for both MabThera and Xeloda, head of oncology and chief marketing officer, before taking
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
Biosimilars: Getting the flock to market
The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
-
Account Director, Medical Education
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
-
Senior Medical Writer
-
Competitive salary and benefits
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
-
Director – Healthcare PR
-
Salary TBC
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
Frontera Group
Welcome to Frontera Group where our agencies immerse you into the world of the patient....
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
